Lenalidomide Market Expects $15.67 Billion By 2032, CAGR: 4.7%

Lenalidomide Market Size Worth $15.67 Billion By 2032 | CAGR: 4.7%

The global lenalidomide market size is expected to reach USD 15.67 billion by 2032, according to a new study by Polaris Market Research. The report “Lenalidomide Market Share, Size, Trends, Industry Analysis Report, By Type (5mg,10mg,15mg,25mg); By Application; By End-User; By Dosage; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growth of lenalidomide is highly influenced by the increasing number of cancer cases worldwide. The higher efficiency of this drug in treating multiple myeloma, myelodysplastic syndromes, and lymphoma patients is anticipated to promote its demand in the marketplace. Pharmaceutical companies use Revlimid as a brand name in the marketing of lenalidomide.

The rising initiatives by pharmaceutical companies to expand their brand coverage in the lenalidomide market are likely to stimulate the growth of the global market, as they can enhance the accessibility of medicine. For instance, in March 2023, Natco Pharma unveiled the additional strengths of Revlimid in its latest version with 2.5 mg and 20 mg strengths in the United States through its marketing agent, Teva Pharmaceuticals.

Furthermore, pharmaceutical firms are engaging in development activities related to lenalidomide, driving the expansion of the global market. According to the Start on Therapeutics report, STAR-LLD, the infusion of lower-dose lenalidomide into the blood was demonstrated to be the optimal treatment over Revlimid in some myeloma patients.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/lenalidomide-market/request-for-sample

The increasing incidence of blood cancer is facilitating the need for drugs, including lenalidomide, in the marketplace, driven by its profound ability to treat the disease. According to the American Cancer Society 2023 Report, in the United States, there will be 609,820 deaths caused by cancer, and the estimated number of new cases is 1,958,310. This trend is emphasizing the need to enhance the accessibility of lenalidomide for patients.

Pharmaceutical firms are resolving patent issues associated with the production of lenalidomide with the settlements, contributing to the increased supply of this drug in the global market. For instance, in 2023, Sun Pharma received approval from the USFDA to market generic lenalidomide capsules in several strengths after entering into a settlement agreement with Celgene Corporation. With this, it can produce an unlimited quantity after January 2026 in the U.S., fueling the supply of this prominent cancer drug during the forecast period.

Lenalidomide Market Report Highlights

  • 5mg capsules segment is anticipated to witness the highest growth in the coming years due to its flexibility.
  • Multiple myeloma segment accounted for the largest market share owing to the prominent performance of lenalidomide in treating multiple myeloma.
  • Hospitals segment is projected to experience a larger revenue share due to the rising number of cancer patients consulting hospitals.
  • APAC is projected to register the fastest growth attributable to the increasing number of patients with cancer-based medical complications.
  • The global players include Ablynx, Actiza, Celgene, Celltrion, Dexa Medical, Exova, LEO Pharma, Natco Pharma, & Toyama Chemical.

Polaris   Market Research has segmented the lenalidomide market report based on type, application, end-user, dosage, and region:

Lenalidomide, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • 5mg Capsules
  • 10mg Capsules
  • 15mg Capsules
  • 25mg Capsules

Lenalidomide, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Multiple myeloma (MM)
  • Myelodysplastic syndromes (MDS)
  • Lymphoma
  • Others

Lenalidomide, End-User Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals
  • Cancer Treatment Centers
  • Research Institutes

Lenalidomide, Dosage Outlook (Revenue - USD Billion, 2019 - 2032)

  • Capsules
  • Tablets

Lenalidomide, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa